Denali Q2: AVLAYAH Launch Yields $3.6M Revenue; $195M PRV Sale Closes Post-Quarter; Pipeline Reshaped After Parkinson's Failure
DNLI sits 100% above its 52-week low of $12.58.
Summary
Denali's Q2 2026 10-Q reports $3.6M in initial AVLAYAH revenue, a $195M PRV sale closing post-quarter, and pipeline setbacks including the Phase 2b LUMA failure in Parkinson's disease.
Key Events · Earnings and Guidance · DNLI
-
AVLAYAH Launch Revenue
The first full quarter of AVLAYAH sales brought in $3.6 million in net product revenue, with cost of goods sold at just $0.1 million, reflecting inventory that had been expensed previously.
-
$195M PRV Sale Closes Post-Quarter
A Rare Pediatric Disease Priority Review Voucher was sold for $195 million; the transaction closed on July 27, 2026, with proceeds arriving after the quarter ended, further strengthening cash reserves.
-
Pipeline Setback: LUMA Failure
The Phase 2b LUMA study of BIIB122 in early-stage Parkinson's disease missed both primary and secondary endpoints, prompting Denali and Biogen to halt development in idiopathic Parkinson's.
-
Takeda Terminates PTV:PGRN Collaboration
Takeda ended the co-development deal for DNL593 (PTV:PGRN) in frontotemporal dementia; Denali regained full rights and is continuing the Phase 1/2 study on its own.
Analysis · DNLI · Life Sciences
Denali's first full quarter with AVLAYAH on the market generated $3.6 million in net product revenue, a modest start for its Hunter syndrome therapy. More impactful is the $195 million priority review voucher sale that closed in July, adding significant non-dilutive cash to a balance sheet that held $940 million at quarter-end. The pipeline saw a major setback with the Phase 2b LUMA failure in Parkinson's, ending the Biogen-partnered BIIB122 program in idiopathic disease, though a separate LRRK2 study continues. Takeda also walked away from the PTV:PGRN collaboration. These pipeline cuts reduce near-term catalysts but sharpen focus on the company's wholly owned programs. The Royalty Pharma deal added $200 million in March but comes with a 9.25% royalty on AVLAYAH sales and a 12% effective interest cost, a non-cash expense that will weigh on reported earnings. Overall, Denali is well-funded through at least mid-2027, but the commercial launch is in its infancy and the pipeline has narrowed.
At the time of this filing, DNLI was trading at $25.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.9B. The 52-week trading range was $12.58 to $27.30. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.